Remarkably, treatment of J82 bladder cancer cells that carry oncogenic HRAS with romidepsin leads to increased apoptosis (controlled by ERK-pathway activation and ROS production), as compared to the parental J82 cells that host wild-type RAS genes. Here, HRAS is linked to urinary bladder carcinoma.